{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T01:17:07Z","timestamp":1778116627825,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020206","name":"Korea Dementia Research Center","doi-asserted-by":"publisher","award":["HU20C0492"],"award-info":[{"award-number":["HU20C0492"]}],"id":[{"id":"10.13039\/100020206","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>N<\/jats:italic>-(3-fluoropropyl)-2\u03b2-carboxymethoxy-3\u03b2-(4-iodophenyl) nortropane (FP-CIT), the representative cocaine derivative used in dopamine transporter imaging, is a promising biomarker, as it reflects the severity of Parkinson\u2019s disease (PD). <jats:sup>123<\/jats:sup>I- and <jats:sup>18<\/jats:sup>F-labeled FP-CIT has been used for PD diagnosis. However, preclinical studies evaluating [<jats:sup>18<\/jats:sup>F]FP-CIT as a potential diagnostic biomarker are scarce. Among translational research advancements from bench to bedside, translating preclinical findings into clinical practice is one-directional. The aim of this study is to employ a circular approach, beginning back from the preclinical stage, progressing to the supplementation of [<jats:sup>18<\/jats:sup>F]FP-CIT, and subsequently returning to clinical application. We investigated the pharmacokinetic properties of [<jats:sup>18<\/jats:sup>F]FP-CIT and its efficacy for PD diagnosis using murine models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Biodistribution, metabolite and excretion analyses were performed in mice and PD models were induced in rats using 6-hydroxydopamine (6-OHDA). The targeting efficiency of [<jats:sup>18<\/jats:sup>F]FP-CIT for the dopamine receptor was assessed through animal PET\/CT imaging. Subsequently, correlation analysis was conducted between animal PET\/CT imaging results and immunohistochemistry (IHC) targeting tyrosine hydroxylase. Rapid circulation was confirmed after [<jats:sup>18<\/jats:sup>F]FP-CIT injection. [<jats:sup>18<\/jats:sup>F]FP-CIT reached the highest uptake of 23.50\u2009\u00b1\u200912.46%ID\/g in the striatum 1\u00a0min after injection, and it was rapidly excreted within 60\u00a0min. The major metabolic organs of [<jats:sup>18<\/jats:sup>F]FP-CIT were confirmed to be the intestines, liver, and kidneys. Its uptake in the intestine was approximately 5% ID\/g. The uptake in the liver gradually increased, with excretion beginning after reaching a maximum after 60\u00a0min. The kidneys exhibited rapid elimination after 10\u00a0min. In the excretion study, rapid elimination was verified, with 21.46\u2009\u00b1\u20099.53% of the compound excreted within a 6\u00a0h period. Additionally, the efficacy of [<jats:sup>18<\/jats:sup>F]FP-CIT PET was demonstrated in the PD model, with a high correlation with IHC for both the absolute value (R\u2009=\u20090.803, <jats:italic>p<\/jats:italic>\u2009=\u20090.0017) and the ratio value (R\u2009=\u20090.973, <jats:italic>p<\/jats:italic>\u2009=\u20090.0011).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study fills the gap regarding insufficient preclinical studies on [<jats:sup>18<\/jats:sup>F]FP-CIT, including its ADME, metabolites, and efficiency. The pharmacological results, including accurate diagnosis, rapid circulation, and [<jats:sup>18<\/jats:sup>F]FP-CIT excretion, provide complementary evidence that [<jats:sup>18<\/jats:sup>F]FP-CIT can be used safely and efficiently to diagnose PD in clinics, although it is already used in clinics.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-024-01121-6","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T14:13:50Z","timestamp":1720016030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson\u2019s disease: pharmacokinetic and efficacy analysis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3339-5825","authenticated-orcid":false,"given":"Jae Hun","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-8497","authenticated-orcid":false,"given":"Min Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-3817","authenticated-orcid":false,"given":"Kyongkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2025-6276","authenticated-orcid":false,"given":"Keumrok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4455-6306","authenticated-orcid":false,"given":"Hyunwoo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-9519","authenticated-orcid":false,"given":"Hee Seup","family":"Kil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7206-6658","authenticated-orcid":false,"given":"Soon Jeong","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1901-8238","authenticated-orcid":false,"given":"Jae Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9862-3286","authenticated-orcid":false,"given":"Dae Yoon","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7140-354X","authenticated-orcid":false,"given":"Yong Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"1121_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","volume":"172","author":"A Elbaz","year":"2016","unstructured":"Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson\u2019s disease. Rev Neurol (Paris). 2016;172:14\u201326. https:\/\/doi.org\/10.1016\/j.neurol.2015.09.012.","journal-title":"Rev Neurol (Paris)"},{"key":"1121_CR2","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13.","journal-title":"Nat Rev Dis Primers"},{"key":"1121_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","volume":"10","author":"M Politis","year":"2014","unstructured":"Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10:708\u201322. https:\/\/doi.org\/10.1038\/nrneurol.2014.205.","journal-title":"Nat Rev Neurol"},{"key":"1121_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12264-017-0202-6","volume":"34","author":"ZY Liu","year":"2018","unstructured":"Liu ZY, Liu FT, Zuo CT, Koprich JB, Wang J. Update on molecular imaging in Parkinson\u2019s disease. Neurosci Bull. 2018;34:330\u201340. https:\/\/doi.org\/10.1007\/s12264-017-0202-6.","journal-title":"Neurosci Bull"},{"key":"1121_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.apradiso.2014.06.016","volume":"94","author":"M Lee","year":"2014","unstructured":"Lee M, Ryu YH, Cho WG, Jeon TJ, Lyoo CH, Kang YW, et al. Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans-[18F]Mefway. Appl Radiat Isot. 2014;94:30\u20134. https:\/\/doi.org\/10.1016\/j.apradiso.2014.06.016.","journal-title":"Appl Radiat Isot"},{"key":"1121_CR6","first-page":"102","volume":"6","author":"N Ibrahim","year":"2016","unstructured":"Ibrahim N, Kusmirek J, Struck AF, Floberg JM, Perlman SB, Gallagher C, et al. The sensitivity and specificity of F-DOPA PET in a movement disorder clinic. Am J Nucl Med Mol Imaging. 2016;6:102\u20139.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1121_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnins.2018.00612","volume":"12","author":"FN Emamzadeh","year":"2018","unstructured":"Emamzadeh FN, Surguchov A. Parkinson\u2019s disease: biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612. https:\/\/doi.org\/10.3389\/fnins.2018.00612.","journal-title":"Front Neurosci"},{"key":"1121_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/archneur.59.4.580","volume":"59","author":"MJ Ribeiro","year":"2002","unstructured":"Ribeiro MJ, Vidailhet M, Loc\u2019h C, Dupel C, Nguyen JP, Ponchant M, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol. 2002;59:580\u20136. https:\/\/doi.org\/10.1001\/archneur.59.4.580.","journal-title":"Arch Neurol"},{"key":"1121_CR9","doi-asserted-by":"publisher","first-page":"11234","DOI":"10.3390\/ijms222011234","volume":"22","author":"G Palermo","year":"2021","unstructured":"Palermo G, Giannoni S, Bellini G, Siciliano G, Ceravolo R. Dopamine transporter imaging, current status of a potential biomarker: a comprehensive review. Int J Mol Sci. 2021;22:11234. https:\/\/doi.org\/10.3390\/ijms222011234.","journal-title":"Int J Mol Sci"},{"key":"1121_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1212\/wnl.52.6.1206","volume":"52","author":"M Ichise","year":"1999","unstructured":"Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F, et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology. 1999;52:1206\u201314. https:\/\/doi.org\/10.1212\/wnl.52.6.1206.","journal-title":"Neurology"},{"key":"1121_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12883-021-02470-8","volume":"21","author":"RM Hutchison","year":"2021","unstructured":"Hutchison RM, Evans KC, Fox T, Yang M, Barakos J, Bedell BJ, et al. Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson\u2019s disease trial. BMC Neurol. 2021;21:459. https:\/\/doi.org\/10.1186\/s12883-021-02470-8.","journal-title":"BMC Neurol"},{"key":"1121_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2967\/jnumed.111.101436","volume":"53","author":"V Sossi","year":"2012","unstructured":"Sossi V, Dinelle K, Jivan S, Fischer K, Holden JE, Doudet D. In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET. J Nucl Med. 2012;53:813\u201322. https:\/\/doi.org\/10.2967\/jnumed.111.101436.","journal-title":"J Nucl Med"},{"key":"1121_CR13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.112.105379","volume":"54","author":"K Tatsch","year":"2013","unstructured":"Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med. 2013;54:1331\u20138. https:\/\/doi.org\/10.2967\/jnumed.112.105379.","journal-title":"J Nucl Med"},{"key":"1121_CR14","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacology review(s); application number 022454 (2009). Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022454sOrig1s000PharmR.pdf. Accessed 12 Apr 2022."},{"key":"1121_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/(SICI)1098-2396(199704)25:4<345::AID-SYN5>3.0.CO;2-A","volume":"25","author":"U Scheffel","year":"1997","unstructured":"Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse. 1997;25:345\u20139. https:\/\/doi.org\/10.1002\/(SICI)1098-2396(199704)25:4%3c345::AID-SYN5%3e3.0.CO;2-A.","journal-title":"Synapse"},{"key":"1121_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13139-014-0286-0","volume":"48","author":"M Seo","year":"2014","unstructured":"Seo M, Oh M, Cho M, Chung SJ, Lee CS, Kim JS. The effect of SSRIs on the binding of 18F-FP-CIT in Parkinson patients: a retrospective case control study. Nucl Med Mol Imaging. 2014;48:287\u201394. https:\/\/doi.org\/10.1007\/s13139-014-0286-0.","journal-title":"Nucl Med Mol Imaging"},{"key":"1121_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/syn.22032","volume":"72","author":"I Lee","year":"2018","unstructured":"Lee I, Kim JS, Park JY, Byun BH, Park SY, Choi JH, et al. Head-to-head comparison of 18F-FP-CIT and 123I-FP-CIT for dopamine transporter imaging in patients with Parkinson\u2019s disease: a preliminary study. Synapse. 2018;72: e22032. https:\/\/doi.org\/10.1002\/syn.22032.","journal-title":"Synapse"},{"key":"1121_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/(SICI)1099-1077(199611)11:6<483::AID-HUP818>3.0.CO;2-9","volume":"11","author":"KA Bergstr\u00f6m","year":"1996","unstructured":"Bergstr\u00f6m KA, Halldin C, Lundkvist C, Swahn CG, \u00c5kerman KK, Kuikka JT, et al. Characterization of C-11 or I-123 labelled \u03b2-CIT-FP and \u03b2-CIT-FE metabolism measured in monkey and human plasma. Identification of two labelled metabolites with HPLC. Hum Psychopharmacol. 1996;11:483\u201390. https:\/\/doi.org\/10.1002\/(SICI)1099-1077(199611)11:6%3c483::AID-HUP818%3e3.0.CO;2-9.","journal-title":"Hum Psychopharmacol"},{"key":"1121_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s0969-8051(97)00077-2","volume":"24","author":"C Lundkvist","year":"1997","unstructured":"Lundkvist C, Halldin C, Ginovart N, Swahn CG, Farde L. [18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol. 1997;24:621\u20137. https:\/\/doi.org\/10.1016\/s0969-8051(97)00077-2.","journal-title":"Nucl Med Biol"},{"key":"1121_CR20","first-page":"1521","volume":"39","author":"K Kazumata","year":"1998","unstructured":"Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521\u201330.","journal-title":"J Nucl Med"},{"key":"1121_CR21","first-page":"425","volume":"42","author":"JS Kim","year":"2008","unstructured":"Kim JS. Practical approach for the clinical use of dopamine transporter imaging. Nucl Med Mol Imaging. 2008;42:425\u201334.","journal-title":"Nucl Med Mol Imaging"},{"key":"1121_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/s0969-8051(96)00133-3","volume":"23","author":"QH Zheng","year":"1996","unstructured":"Zheng QH, Mulholland GK. Improved synthesis of beta-CIT and [11C]Beta-CIT labeled at nitrogen or oxygen positions. Nucl Med Biol. 1996;23:981\u20136. https:\/\/doi.org\/10.1016\/s0969-8051(96)00133-3.","journal-title":"Nucl Med Biol"},{"key":"1121_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1021\/jm00002a020","volume":"38","author":"FI Carroll","year":"1995","unstructured":"Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, et al. Cocaine and 3 beta-(4\u2032-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J Med Chem. 1995;38:379\u201388. https:\/\/doi.org\/10.1021\/jm00002a020.","journal-title":"J Med Chem"},{"key":"1121_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s11307-020-01485-w","volume":"22","author":"SJ Oh","year":"2020","unstructured":"Oh SJ, Ahn H, Jung KH, Han SJ, Nam KR, Kang KJ, et al. Evaluation of the neuroprotective effect of microglial depletion by CSF-1R inhibition in a Parkinson\u2019s animal model. Mol Imaging Biol. 2020;22:1031\u201342. https:\/\/doi.org\/10.1007\/s11307-020-01485-w.","journal-title":"Mol Imaging Biol"},{"key":"1121_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0014-2999(76)90352-6","volume":"40","author":"PH Kelly","year":"1976","unstructured":"Kelly PH, Iversen SD. Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol. 1976;40:45\u201356. https:\/\/doi.org\/10.1016\/0014-2999(76)90352-6.","journal-title":"Eur J Pharmacol"},{"key":"1121_CR26","doi-asserted-by":"publisher","first-page":"50303","DOI":"10.3791\/50303","volume":"76","author":"SM Fleming","year":"2013","unstructured":"Fleming SM, Ekhator OR, Ghisays V. Assessment of sensorimotor function in mouse models of Parkinson\u2019s disease. J Vis Exp. 2013;76:50303. https:\/\/doi.org\/10.3791\/50303.","journal-title":"J Vis Exp"},{"key":"1121_CR27","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1021\/acs.molpharmaceut.7b00351","volume":"14","author":"SJ Oh","year":"2017","unstructured":"Oh SJ, Kim MH, Han SJ, Kang KJ, Ko IO, Kim Y, et al. Preliminary PET study of 18F-FC119S in normal and Alzheimer\u2019s disease models. Mol Pharm. 2017;14:3114\u201320. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00351.","journal-title":"Mol Pharm"},{"key":"1121_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0969-8051(95)00029-w","volume":"22","author":"C Lundkvist","year":"1995","unstructured":"Lundkvist C, Halldin C, Swahn CG, Hall H, Karlsson P, Nakashima Y, et al. [O-Methyl-11C]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol. 1995;22:905\u201313. https:\/\/doi.org\/10.1016\/0969-8051(95)00029-w.","journal-title":"Nucl Med Biol"},{"key":"1121_CR29","first-page":"961","volume":"44","author":"W Robeson","year":"2003","unstructured":"Robeson W, Dhawan V, Belakhlef A, Ma Y, Pillai V, Chaly T, et al. Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects. J Nucl Med. 2003;44:961\u20136.","journal-title":"J Nucl Med"},{"key":"1121_CR30","first-page":"52","volume":"37","author":"C Lundkvist","year":"1995","unstructured":"Lundkvist C, Halldin C, Swahn CG, et al. Synthesis of 11C or 18F-labelled analogues of \u03b2-CIT. Labelling in different positions and PET evaluation in cynomolgus monkeys. J Label Cmpds Radiopharm. 1995;37:52\u20134.","journal-title":"J Label Cmpds Radiopharm"},{"key":"1121_CR31","first-page":"147","volume":"9","author":"GP Gerasimou","year":"2006","unstructured":"Gerasimou GP, Aggelopoulou TC, Costa DC, Gotzamani-Psarrakou A. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders. Nucl Med Rev Cent East Eur. 2006;9:147\u201353.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"1121_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-009-1267-x","volume":"37","author":"J Darcourt","year":"2010","unstructured":"Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443\u201350. https:\/\/doi.org\/10.1007\/s00259-009-1267-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1121_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1098-2396(199711)27:3<183::AID-SYN4>3.0.CO;2-9","volume":"27","author":"J Booij","year":"1997","unstructured":"Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, et al. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse. 1997;27:183\u201390. https:\/\/doi.org\/10.1002\/(SICI)1098-2396(199711)27:3%3c183::AID-SYN4%3e3.0.CO;2-9.","journal-title":"Synapse"},{"key":"1121_CR34","volume-title":"Parkinson\u2019s disease: pathogenesis and clinical aspects","author":"EA Konnova","year":"2018","unstructured":"Konnova EA, Swanberg M. Animal models of Parkinson\u2019s disease. In: Stoker TB, Greenland JC, editors. Parkinson\u2019s disease: pathogenesis and clinical aspects. Brisbane: Codon Publications; 2018."},{"key":"1121_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108789","volume":"114","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Huang N, Chen M, Jin H, Nie J, Shi J, et al. Procyanidin protects against 6-hydroxydopamine-induced dopaminergic neuron damage via the regulation of the PI3K\/Akt signalling pathway. Biomed Pharmacother. 2019;114: 108789. https:\/\/doi.org\/10.1016\/j.biopha.2019.108789.","journal-title":"Biomed Pharmacother"},{"key":"1121_CR36","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.4103\/1673-5374.235077","volume":"13","author":"L Lin","year":"2018","unstructured":"Lin L, Ye J, Zhang H, Han ZF, Zheng ZH. Degree of dopaminergic degeneration measured by 99mTc-TRODAT-1 SPECT\/CT imaging. Neural Regen Res. 2018;13:1281\u20137. https:\/\/doi.org\/10.4103\/1673-5374.235077.","journal-title":"Neural Regen Res"},{"key":"1121_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/2191-219X-3-46","volume":"3","author":"S B\u00e4ck","year":"2013","unstructured":"B\u00e4ck S, Raki M, Tuominen RK, Raasmaja A, Bergstr\u00f6m K, M\u00e4nnist\u00f6 PT. High correlation between in vivo [123I]\u03b2-CIT SPECT\/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats. EJNMMI Res. 2013;3:46. https:\/\/doi.org\/10.1186\/2191-219X-3-46.","journal-title":"EJNMMI Res"},{"key":"1121_CR38","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.neuroimage.2005.03.034","volume":"26","author":"G Andringa","year":"2005","unstructured":"Andringa G, Drukarch B, Bol JG, de Bruin K, Sorman K, Habraken JB, et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson\u2019s disease. Neuroimage. 2005;26:1150\u20138. https:\/\/doi.org\/10.1016\/j.neuroimage.2005.03.034.","journal-title":"Neuroimage"},{"key":"1121_CR39","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1007\/s002590050170","volume":"24","author":"A Abi-Dargham","year":"1997","unstructured":"Abi-Dargham A, Innis RB, Wisniewski G, Baldwin RM, Neumeyer JL, Seibyl JP. Human biodistribution and dosimetry of iodine-123-fluoroalkyl analogs of beta-CIT. Eur J Nucl Med. 1997;24:1422\u20135. https:\/\/doi.org\/10.1007\/s002590050170.","journal-title":"Eur J Nucl Med"},{"key":"1121_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s002590050190","volume":"25","author":"J Booij","year":"1998","unstructured":"Booij J, Busemann Sokole E, Stabin MG, Janssen AG, de Bruin K, van Royen EA. Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998;25:24\u201330.","journal-title":"Eur J Nucl Med"},{"key":"1121_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2967\/jnumed.111.100784","volume":"53","author":"DS Djang","year":"2012","unstructured":"Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53:154\u201363. https:\/\/doi.org\/10.2967\/jnumed.111.100784.","journal-title":"J Nucl Med"},{"key":"1121_CR42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.apradiso.2013.09.006","volume":"82","author":"M Sydoff","year":"2013","unstructured":"Sydoff M, Lizana H, Mattsson S, Stabin MG, Leide-Svegborn S. Determination of the biodistribution and dosimetry of 123I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT\/CT imaging. Appl Radiat Isot. 2013;82:300\u20137. https:\/\/doi.org\/10.1016\/j.apradiso.2013.09.006.","journal-title":"Appl Radiat Isot"},{"key":"1121_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-021-00873-9","volume":"12","author":"W Lehnert","year":"2022","unstructured":"Lehnert W, Riss PJ, Hurtado de Mendoza A, Lopez S, Fernandez G, Ilheu M, et al. Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders. EJNMMI Res. 2022;12:1. https:\/\/doi.org\/10.1186\/s13550-021-00873-9.","journal-title":"EJNMMI Res"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01121-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-024-01121-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01121-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T14:17:25Z","timestamp":1720016245000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-024-01121-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1186\/s13550-024-01121-6","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with ARRIVE guidelines, and the protocol adhering to ethical guidelines was approved by the IACUC at the Korea Institute of Radiological and Medical Sciences (KIRAMS, IACUC No. KIRAMS2021-0114).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}